Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Oramed Pharma Signs $50 Million Diabetes Deal with Sinopharm

publication date: Jul 7, 2015
In a dramatic turnaround, Oramed Pharma of Jerusalem signed a LOI to complete a $50 million deal for China rights to its clinical-stage oral insulin with Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development Co. Last week, Oramed announced a similar deal (though not identical) with Wuzhou Zhongheng Group, an agreement that apparently fell apart. Sinopharm/Hefei paid $500,000 for 60 days of exclusive talks with Oramed, while final terms of the agreement are negotiated. More details....

Stock Symbols: (NSDQ: ORMP) (SHA: 600252)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here